Lorlatinib (Lorbrena)

Ingredients: Lorlatinib
Dosage Form: Capsules
Innovator’s Brand Name: Lorbrena
Generic Brand Name: Lornatib
Generic Manufacturer: Ziska Pharma

Indications:
Lorlatinib is indicated for the treatment of adult patients with ALK‑positive advanced non‑small cell lung cancer who have progressed on one or more prior ALK inhibitor therapies (e.g., alectinib, ceritinib, or crizotinib).

Dosage and Administration:
The recommended dose is 100 mg orally once daily. If not tolerated, reduce sequentially to 75 mg and then to 50 mg once daily. If a dose is missed, follow your physician’s instructions; do not double the next dose to make up for a missed one.

Adverse Reactions:
Common adverse reactions include hypercholesterolemia, hypertriglyceridemia, edema, peripheral neuropathy, cognitive and mood changes, fatigue, and weight gain.

Storage:
Store in a dry place below 30 °C, protected from moisture and light, and keep out of reach of children.

Package Insert (Prescribing Information):

Download Link